The ERA-NET TRANSCAN-3 , in continuity of the preceding ERA-NET TRANSCAN-2, aims to promote a transnational collaborative approach between scientific teams in demanding areas of translational cancer research, to produce significant results of higher quality and impact, and share data and infrastructures.
The first Joint Transnational Call for Proposals 2021 (JTC 2021), with the contribution of the European Commission, will focus on:
Despite advances in immunotherapies, obstacles and challenges, including limited response rates, the inability to predict clinical efficacy, and potential side effects such as autoimmune reactions or cytokine release syndromes, remain and hinder further applications of immunotherapies in clinics. Thus, a deeper understanding of the TME, able to dissect distinct classes and subclasses of it, is essential for deciphering new mechanisms of immunotherapies, defining new predictive biomarkers, and identifying novel therapeutic targets.
This topic, at the intersection of laboratory and clinical research in immuno-oncology, will comprise two general aims, which concur to the possible clinical applications:
For more information:Joint Call (JTC 2021) (transcan.eu)
Launch: April 6th, 2021
Deadline for pre-proposals submission: June 29th, 2021
Pre-selection results: November 5th, 2021
Deadline for full proposal submission: December 20th, 2021
Funding decision: July 2022